Navigation Links
Neogen reports 27% increase in quarterly net income
Date:3/26/2013

LANSING, Mich., March 26, 2013 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) announced today that its net income for the third quarter of FY 2013, which ended Feb. 28, increased 27% to $6,652,000, or $0.27 per share, compared to the prior year's third quarter net income of $5,244,000, or $0.22 a share. Year to date, nine-month net income increased 22% to $20,158,000, or $0.83 per share, compared to $16,485,000, or $0.69 per share, in the prior year.

Third quarter revenues were $51,055,000, an increase of 14% from the previous year's third quarter revenues of $44,912,000. Year to date, nine-month revenues increased 12% in the current fiscal year to $151,522,000 from FY 2012's $135,501,000.

"We are pleased to report another record-breaking quarter for revenues and even bigger income growth," said James Herbert, Neogen's chief executive officer and chairman. "The growth and improved earnings are the result of increased market share, new products, and revenues from recent acquisitions. The quarter also saw the opening of several new market opportunities that should help fuel future growth."

Neogen's gross margin increased to 53.5% of sales in its third quarter, compared to 51.0% of sales for FY 2012's third quarter. For the year to date, gross margins were also 53.5%, reflective of a shift in product mix toward higher margin products, including food safety diagnostics, rodenticides, new products acquired in the Macleod acquisition, and manufacturing efficiencies. Operating expenses increased during the quarter, primarily as a result of investments made in the company's sales and marketing infrastructure, and personnel and related expenses absorbed through acquisition.

"Cost reductions in raw material and productivity improvements, in addition to the favorable product mix, have pushed up gross margins," said Lon Bohannon, Neogen's president and chief
'/>"/>

SOURCE Neogen Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neogen Corporation Announces 2nd Quarter Results Conference Call
2. Neogen Reports Second Quarter Results
3. Neogen Launches Fully Quantitative Lateral Flow Test for DON
4. Neogen launches the fastest molecular pathogen test
5. Neogen acquires Igenity from Merial
6. Neogen Corporation Announces Year-End Results Conference Call
7. Neogen reports year end results
8. Neogen Corporation Announces 1st Quarter Results Conference Call
9. Neogen reports 30% increase in quarterly net income
10. Neogen Corporation Announces 3rd Quarter Results Conference Call
11. Neogen launches rapid tests for ractopamine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic disease, today announced the next step in ... premier bio-analytics solutions provider with the naming of current ... and Chief Executive Officer, while current Chairman of the ... to serve as Chairman. These changes are effective January ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that the ... PVM technology , is now available. The new ... continuously captures high-resolution images under a wide range ... a report pairing the most relevant images to ... compelling blend of high resolution images and trend ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
(Date:12/13/2014)... and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... less rosy indicators in overall global economic growth, Eugene ... optics and photonics , said in a featured talk ... on 5 December at the National Chung Hsing University ... which is being integrated into future energy supplies and ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5
... New System to Streamline Process, Drive Value from ... Software Inc., a leading,provider of web-based employee performance ... been selected by Quiznos to provide a system,for ... is a,national chain with over 5000 franchise restaurants, ...
... Alimera Sciences,and pSivida Ltd (Nasdaq: PSDV ... have amended their license and collaboration agreement relating ... for,diabetic macular edema (DME), and other Medidur products. ... of Medidur FA from 50 to 80,percent in ...
... Million Distribution Contract from Anhui ... Huayuan Pharmaceutical Co., ... Co., Inc., (OTC Bulletin Board: TYNP), a manufacturer and,supplier ... today announced that the Company has been granted SFDA,approval ...
Cached Biology Technology:Quiznos Selects Halogen for Fresh Approach to Talent Management 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 3Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 4Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 2Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 3
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... Taking aim at a leading cause of ... at the Massachusetts Biologic Laboratories (MBL) of the University of ... that neutralizes the Hepatitis C virus (HCV). The new ... infection by the virus in a pre-clinical animal model of ...
... details of a membership agreement with BioMed Central to ... researchers. Pfizer,s BioMed Central membership arrangement means that ... researcher employed or funded by Pfizer when they submit ... peer-reviewed open access journals. By funding open access publication ...
... of Guam Associate Professor Laurie Raymundo is senior editor ... and management of coral diseases, " Coral Disease Handbook: ... summarizes the most recently developed methods for studying the ... the book is a set of identification cards for ...
Cached Biology News:Novel antibody prevents infection by hepatitis C virus 2Novel antibody prevents infection by hepatitis C virus 3
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-DM 2 x 109 cells...
Rabbit polyclonal to Staphylococcus Enterotoxin E (Biotin) ( Abpromise for all tested applications)....
... Ribonuclease III (RNase III) from E. ... double-stranded RNA (dsRNA) to dsRNA fragments that ... dsRNA results in dsRNA fragments of 12-15 ... RNA composed of canonical ribonucleotides as well ...
...
Biology Products: